Nektar Therapeutics
NKTR
146 hedge funds and large institutions have $79.3M invested in Nektar Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 49 reducing their positions, and 72 closing their positions.
509% more call options, than puts
Call options by funds: $329K | Put options by funds: $54K
1.23% less ownership
Funds ownership: 6.08% → 4.86% (-1.2%)
25% less funds holding
Funds holding: 194 → 146 (-48)
35% less capital invested
Capital invested by funds: $121M → $79.3M (-$41.8M)
45% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 49
67% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11.5M |
| 2 |
MAM
Monaco Asset Management
Monaco
|
+$6.58M |
| 3 |
SCM
Sio Capital Management
New York
|
+$4.97M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.86M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$22.7M |
| 2 |
BlackRock
New York
|
-$19.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.44M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.45M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$2.62M |
NKTR Hedge Fund Activity: Q2 2023 in Review
146 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2023, worth a combined $79.3M — down 35% from $121M a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of NKTR and 24 opened new positions — a net loss of 48 holders — while 49 trimmed existing stakes and 27 added.
The largest buyer was Deep Track Capital, adding an estimated $11.5M. The largest seller was Invesco, cutting an estimated $22.7M.
- 146 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2023, down from 194 in Q1 2023.
- Funds reported $79.3M of Nektar Therapeutics stock for Q2 2023, down 35% quarter-over-quarter.
- 24 funds opened new Nektar Therapeutics positions in Q2 2023 and 72 closed out, a net change of -48 holders.
- The largest Nektar Therapeutics buyer in Q2 2023 was Deep Track Capital, an estimated $11.5M added.
- The largest Nektar Therapeutics seller in Q2 2023 was Invesco, an estimated $22.7M sold.
Based on aggregated 13F filings for Q2 2023.